Biologic drug makers will soon have to alert the Federal Trade Commission and Department of Justice of agreements, including patent litigation settlements, they reach with biosimilar applicants. The new reporting requirement...more
Attention in the US during 2016 will be on the presidential campaign, and the election in November will bring a change in the "antitrust guard" at the top of the DOJ and FTC – even if a Democrat wins – that will drive the...more
1/12/2016
/ China ,
Corporate Counsel ,
Criminal Penalties ,
Department of Justice (DOJ) ,
Disgorgement ,
Drug Pricing ,
EU ,
European Commission ,
Federal Trade Commission (FTC) ,
FRAND ,
Mergers ,
MOFCOM ,
Patent Assertion Entities ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Price-Fixing ,
Standard Essential Patents ,
Technology Sector